RMS Achieves Milestone with Third Successful Sickle Cell Treatment Using Gene-Editing Therapy

Manama:The Royal Medical Services (RMS) in Bahrain has successfully treated its third sickle cell disease patient with Casgevy, a cutting-edge gene-editing therapy. This development marks a significant milestone in Bahrain's advancement of specialized genetic treatments, accomplished through the Bahrain Oncology Centre.

According to Bahrain News Agency, this achievement is attributed to the ongoing support of His Majesty King Hamad bin Isa Al Khalifa, the Supreme Commander of the Armed Forces, and His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister, as well as Field Marshal Shaikh Khalifa bin Ahmed Al Khalifa, Commander-in-Chief of the Bahrain Defence Force. Their backing has been instrumental in enhancing medical and technical capabilities and aligning with global therapeutic innovations.

On this occasion, Lieutenant General Dr Shaikh Mohammed bin Abdullah Al Khalifa, President of the Supreme Council of Health; Dr Jalila bint Al Sayyed Jawad Hassan, Minister of Health; and Major General Dr Shaikh Fahad bin Khalifa bin Salman Al Khalifa, Commander of the Royal Medical Services, visited the patient to assess their health and review the treatment's success and recovery progress.

Officials have emphasized that this achievement is a crucial step in advancing specialized healthcare in Bahrain. It highlights the country's growing capabilities in adopting innovative medical treatments and expanding access to advanced genetic therapies for complex hereditary diseases.

The Commander of the Royal Medical Services underscored the significant medical and humanitarian value of the successful treatment, offering patients a chance for a stable life with fewer recurrent pain episodes and complications. He praised the medical, nursing, and technical teams involved and affirmed the RMS's commitment to further developing gene therapy and stem cell transplantation services.

Dr Edward Rowland, Chief Executive Officer of the Bahrain Oncology Centre, stated that the successful treatment reflects the centre's progress in delivering advanced gene therapies. Casgevy requires careful preparation, medical assessment, and continuous clinical monitoring in line with specialized treatment protocols and safety standards.

Casgevy modifies a patient's blood stem cells to stimulate the production of fetal haemoglobin, reducing severe pain episodes associated with sickle cell disease, without the need for a stem cell donor. This therapy represents a significant leap beyond conventional treatments by targeting the underlying mechanisms of the disease, offering prospects for improved long-term health outcomes. The successful treatment of the third patient further enhances the Royal Medical Services' medical achievements and strengthens Bahrain's position in advanced specialized medicine.